For the quarter ending 2025-09-30, APRE has $14,321,316 in assets. $13,718,052 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 13,718,052 | 16,532,199 | ||
| Prepaid expenses and other current assets | 225,936 | 395,011 | ||
| Total current assets | 13,943,988 | 16,927,210 | ||
| Property and equipment, net | 65,236 | 70,665 | ||
| Restricted cash | 40,930 | 40,673 | ||
| Other noncurrent assets | 271,162 | 271,162 | ||
| Total assets | 14,321,316 | 17,309,710 | ||
| Accounts payable | 641,322 | 1,195,838 | ||
| Accrued expenses | 2,039,785 | 1,971,830 | ||
| Total current liabilities | 2,681,107 | 3,167,668 | ||
| Series a convertible preferred stock, 0.001 par value, 40,000,000 shares authorized 31,194 and 56,227 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively-Convertible Preferred Stock Seriesa | 727,361 | 727,361 | ||
| Common stock, 0.001 par value, 400,000,000 shares authorized, 5,979,292 and 5,481,055 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 5,979 | 5,752 | ||
| Additional paid-in capital | 352,722,214 | 352,250,747 | ||
| Accumulated other comprehensive loss | -10,629,534 | -10,628,417 | ||
| Accumulated deficit | -331,185,811 | -328,213,401 | ||
| Total stockholders' equity | 10,912,848 | 13,414,681 | ||
| Total liabilities and stockholders' equity | 14,321,316 | 17,309,710 | ||
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)